169 related articles for article (PubMed ID: 9544263)
21. Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
Sinclair EM; Drucker DJ
Physiology (Bethesda); 2005 Oct; 20():357-65. PubMed ID: 16174875
[TBL] [Abstract][Full Text] [Related]
22. Cloning and functional expression of a human glucagon-like peptide-1 receptor.
Graziano MP; Hey PJ; Borkowski D; Chicchi GG; Strader CD
Biochem Biophys Res Commun; 1993 Oct; 196(1):141-6. PubMed ID: 8216285
[TBL] [Abstract][Full Text] [Related]
23. The primary ligand-binding interaction at the GLP-1 receptor is via the putative helix of the peptide agonists.
Al-Sabah S; Donnelly D
Protein Pept Lett; 2004 Feb; 11(1):9-14. PubMed ID: 14965273
[TBL] [Abstract][Full Text] [Related]
24. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
25. Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues.
López de Maturana R; Treece-Birch J; Abidi F; Findlay JB; Donnelly D
Protein Pept Lett; 2004 Feb; 11(1):15-22. PubMed ID: 14965274
[TBL] [Abstract][Full Text] [Related]
26. Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent.
Doyle ME; Greig NH; Holloway HW; Betkey JA; Bernier M; Egan JM
Endocrinology; 2001 Oct; 142(10):4462-8. PubMed ID: 11564711
[TBL] [Abstract][Full Text] [Related]
27. ["Glucagon-like peptide I": a therapeutic alternative for diabetes mellitus?].
Fehmann HC; Göke B
Dtsch Med Wochenschr; 1994 Feb; 119(8):275-9. PubMed ID: 8112212
[No Abstract] [Full Text] [Related]
28. Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.
Ebinger M; Jehle DR; Fussgaenger RD; Fehmann HC; Jehle PM
Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E88-94. PubMed ID: 10893327
[TBL] [Abstract][Full Text] [Related]
29. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.
Holst JJ; Deacon CF
Curr Opin Pharmacol; 2004 Dec; 4(6):589-96. PubMed ID: 15525549
[TBL] [Abstract][Full Text] [Related]
30. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
[TBL] [Abstract][Full Text] [Related]
31. Central glucagon-like peptide-I in the control of feeding.
Gunn I; O'Shea D; Turton MD; Beak SA; Bloom SR
Biochem Soc Trans; 1996 May; 24(2):581-4. PubMed ID: 8736807
[No Abstract] [Full Text] [Related]
32. Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo.
Baggio LL; Kim JG; Drucker DJ
Diabetes; 2004 Dec; 53 Suppl 3():S205-14. PubMed ID: 15561912
[TBL] [Abstract][Full Text] [Related]
33. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes.
Montrose-Rafizadeh C; Yang H; Wang Y; Roth J; Montrose MH; Adams LG
J Cell Physiol; 1997 Sep; 172(3):275-83. PubMed ID: 9284947
[TBL] [Abstract][Full Text] [Related]
34. Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line.
Fehmann HC; Habener JF
FEBS Lett; 1991 Feb; 279(2):335-40. PubMed ID: 1672112
[TBL] [Abstract][Full Text] [Related]
35. Glucagon-like peptides.
Drucker DJ
Diabetes; 1998 Feb; 47(2):159-69. PubMed ID: 9519708
[TBL] [Abstract][Full Text] [Related]
36. [Glucagon-like peptide-1(GLP-1)].
Wasada T
Nihon Rinsho; 2004 Jun; 62(6):1175-80. PubMed ID: 15206160
[TBL] [Abstract][Full Text] [Related]
37. [Glucagon-like peptide-1 (GLP-1) receptor].
Taminato T
Nihon Rinsho; 2002 Jul; 60 Suppl 7():535-41. PubMed ID: 12238094
[No Abstract] [Full Text] [Related]
38. The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity.
Graziano MP; Hey PJ; Strader CD
Recept Channels; 1996; 4(1):9-17. PubMed ID: 8723643
[TBL] [Abstract][Full Text] [Related]
39. The positive charge at Lys-288 of the glucagon-like peptide-1 (GLP-1) receptor is important for binding the N-terminus of peptide agonists.
Al-Sabah S; Donnelly D
FEBS Lett; 2003 Oct; 553(3):342-6. PubMed ID: 14572647
[TBL] [Abstract][Full Text] [Related]
40. [GIP and GLP-1: multiplicity of regulator mechanisms for insulin secretion].
Thorens B
Journ Annu Diabetol Hotel Dieu; 2004; ():111-25. PubMed ID: 15259310
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
